Skip to main content

Table 3 Comparison of the characteristics of patients who underwent transfusion and those who did not undergo transfusion with data reported for the whole study series and for one-to-one score-matched pair

From: Impact of low skeletal muscle mass index and perioperative blood transfusion on the prognosis for HCC following curative resection

 

Whole study series

 

Propensity score-matched series

 

All patients

(n = 139)

Transfusion

(n = 22)

Non-transfusion (n = 117)

P-value

All patients

(n = 40)

Transfusion

(n = 20)

Non-transfusion (n = 20)

P-value

Male sex

110 (79%)

18 (82%)

92 (79%)

1.000

31 (78%)

16 (80%)

15 (75%)

1.000

Age (years) ≥70

88 (63%)

16 (73%)

72 (62%)

0.348

27 (68%)

15 (75%)

12 (60%)

0.501

BMI (kg/m2) ≥25.0

34 (25%)

4 (18%)

30 (26%)

0.593

10 (25%)

4 (20%)

6 (30%)

0.716

HBV

27 (19%)

3 (14%)

24 (21%)

0.568

5 (13%)

3 (15%)

2 (10%)

1.000

HCV

70 (50%)

12 (55%)

58 (50%)

0.817

20 (50%)

10 (50%)

10 (50%)

1.000

DM

29 (21%)

2 (9%)

27 (23%)

0.165

7 (18%)

2 (10%)

5 (25%)

0.407

NLR

13 (9%)

1 (5%)

12 (10%)

0.481

4 (10%)

1 (5%)

2 (10%)

1.000

PNI

11 (8%)

5 (23%)

6 (5%)

0.015

7 (18%)

5 (25%)

2 (10%)

0.407

GPS ≥1

24 (17%)

7 (32%)

17 (15%)

0.065

13 (33%)

6 (30%)

7 (35%)

1.000

Hb (g/dL)

14.1 (9.4–18.2)

13.5 (9.4–17.8)

14.1 (9.4–18.2)

0.016

13.4 (9.4–17.8)

13.7 (9.4–17.8)

13.2 (9.4–15.3)

0.490

PLT (×104/μL) < 14

45 (32%)

8 (36%)

37 (32%)

0.804

13 (33%)

7 (35%)

6 (30%)

1.000

PT (%) < 70

14 (10%)

1 (5%)

13 (11%)

0.698

2 (5%)

1 (5%)

1 (5%)

1.000

T-Bil (mg/dL) ≥1

29 (21%)

4 (14%)

25 (21%)

0.495

6 (15%)

3 (15%)

3 (15%)

1.000

AST (U/L) ≥ 38

57 (41%)

11 (50%)

46 (39%)

0.357

19 (48%)

11 (55%)

8 (40%)

0.527

ALT (U/L) ≥42

41 (30%)

7 (32%)

34 (29%)

0.802

16 (40%)

7 (35%)

9 (45%)

0.748

ChE (g/dL) < 100

3 (2%)

1 (5%)

2 (2%)

0.406

2 (5%)

1 (5%)

1 (5%)

1.000

Alb (g/dL) < 4

63 (45%)

12 (55%)

51 (44%)

0.361

26 (65%)

10 (50%)

16 (80%)

0.096

ICGR15 (%) ≥ 10

93 (67%)

18 (82%)

75 (64%)

0.059

33 (83%)

18 (90%)

15 (75%)

0.407

AFP (ng/mL) ≥ 10

68 (49%)

15 (68%)

53 (45%)

0.102

24 (60%)

13 (65%)

11 (55%)

0.748

PIVKA-II (mAU/mL) ≥ 40

96 (69%)

21 (96%)

75 (64%)

0.004

35 (88%)

19 (95%)

16 (80%)

0.342

Tumor diameter > 2 cm

112 (81%)

20 (91%)

92 (79%)

0.249

37 (93%)

18 (90%)

19 (95%)

1.000

Tumor number

1 (1–5)

1 (1–5)

1 (1–3)

0.963

1 (1–3)

1 (1–3)

1 (1–3)

0.495

Poor differentiation

20 (14%)

3 (14%)

17 (15%)

1.000

4 (10%)

3 (15%)

1 (5%)

0.605

IM (+)

19 (6%)

4 (18%)

15 (13%)

0.738

4 (10%)

2 (10%)

2 (10%)

1.000

Operation time (min)

303 (66–591)

383 (210–591)

282 (66–582)

< 0.001

374 (127–591)

383 (210–591)

348 (127–582)

0.461

Intraoperative blood loss (g)

506 (0–6055)

820 (250–6055)

230 (0–2467)

< 0.001

500 (40–6055)

820 (250–6055)

450 (40–1181)

0.002

Hospital stay (days)

22 (5–100)

20 (11–80)

17 (5–100)

0.058

20 (11–81)

20 (11–88)

20 (15–81)

0.820

  1. Variables in bold are statistically significant (P<0.05). Continuous variables are expressed as medians (range). Qualitative variables are expressed as numbers (%). Abbreviations: BMI, Hb; hemoglobin, Body mass index; HBV, hepatitis type B; HCV, hepatitis type C, DM, diabetes mellitus; NLR, neutrophil-to-lymphocyte ratio; PNI, prognostic nutritional index; GPS, Glasgow prognostic score; PLT, platelets; PT, prothrombin time; T-Bil, total-bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ChE, cholinesterase; Alb, albumin; ICGR15, indocyanine green retention15; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; IM, intrahepatic metastasis
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us